Matoke® Pharma’s lead pharmaceutical candidate, RO®101, aims to be the ideal wound healing agent, with antimicrobial and biofilm penetration properties. It delivers Reactive Oxygen® for the treatment of Chronic Non-Healing Wounds, including those involving biofilm production as well as multi-drug resistant (MDR) pathogens. This builds on the evidence from our first CE-marked medical device.

Elsewhere, there are currently no existing therapies available or in the pipeline which can penetrate biolfims, stimulate tissue regeneration and provide non-systemic, potent and broad-spectrum antimicrobial treatment. Reactive Oxygen® technology represents a new generation of non-conventional antimicrobial which can also accelerate wound healing and stimulate the immune system. Reactive Oxygen® technology is a major advance in infection management.

Antimicrobial resistance (AMR) is a major global challenge which is expected to kill ten million people every year by 2050, without global action. Reactive Oxygen® is part of the solution.

R&D RO™ technology RO®101